Description: H-FABP, Human, ELISA kit
Fatty acid-binding proteins (FABPs) are a class of cytoplasmic proteins that bind long chain fatty acids. FABPs are small intracellular proteins (~13-14 kDa) with a high degree of tissue specificity. They are abundantly present in various cell types and play an important role in the intracellular utilization of fatty acids, transport and metabolism. There are at least nine distinct types of FABP, each showing a specific pattern of tissue expression. Due to its small size, FABP leaks rapidly out of ischemically damaged necrotic cells leading to a rise in serum levels. Ischemically damaged tissues are characterized histologically by absence (or low presence) of FABP facilitating recognition of such areas. Following acute myocardial infarction (AMI) the small protein H-FABP is rapidly released into the circulation. H-FABP is derived from the human FABP3 gene. Significantly elevated serum/plasma concentrations are found within 3 h after AMI which generally return to normal values within 12 to 24 h. These features make H-FABP a useful research tool for the early assessment or exclusion of AMI, and for the monitoring of a recurrent infarction. Constitutive H-FABP released from the heart after AMI is quantitatively recovered in serum/plasma. Thus assessment of H-FABP is also a very effective tool for the estimation of the infarct size. The human H-FABP kit can also be used for measurement of brain-type FABP, a marker for brain injury detection and for measurement of muscle-type cytosolic fatty acid binding protein (FABPc) in skeletal muscle. In serum/plasma of healthy individuals approximately 1.6 ng/ml of H-FABP is present. H-FABP shows a slight increase with age.
Specifications
| Catalog number |
HK402 |
| Product type |
Assays |
| Quantity |
2 x 96 det. |
| Standard range |
102-25,000 pg/ml |
| Detection level |
102 pg/ml |
| Working volume |
100 µl/well |
| Species |
Human |
| Cross reactivity |
Horse - Yes, Pig - Yes, Salmon - Yes |
| Alias |
FABP3, Muscle fatty acid-binding protein, Mammary-derived growth inhibitor |
| Application |
The human H-FABP ELISA has been developed for the quantitative measurement of natural human H-FABP in serum, plasma and urine. |
| Disease |
Cardiovascular Diseases |
| Principle |
The human H-FABP ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 1½ hours (normal format) or 50 minutes (rapid format).
The efficient format of 1 plate with twelve disposable 8-well strips allows free choice of batch size for the assay.
Samples and standards are captured by a solid bound specific antibody.
Biotinylated tracer antibody will bind to captured human H-FABP.
Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody.
Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB).
The enzyme reaction is stopped by the addition of citric acid.
The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human H-FABP standards (log).
The human H-FABP concentration of samples, which are run concurrently with the standards, can be determined from the standard curve. |
| Storage and Stability |
Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year. |
| Precautions |
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product. |
| References |
1. Guglielmo, C et al; Seasonal dynamics of flight muscle fatty acid binding protein and
catablolic enzymes in a migratory shorebird. Am J Physiol Regulatory Integrative Comp
Physiol 2002, 282: R1405
2. Mensink, M et al; Lifestyle changes and lipid metabolism gene expression and protein
content in skeletal muscle of subjects with impaired glucose tolerance. Diabetologia
2003, 46: 1082
3. Pelsers, M et al; Brain- and heart-type fatty acid-binding proteins in the brain: tissue
distribution and clinical utility. Clin Chem 2004, 50: 1568
4. Pelsers, M et al; Detection of brain injury by fatty acid-binding proteins. Clin chem lab
med 2005, 43: 802
5. Morariu, A et al; Dexamethasone: benefit and prejudice for patients undergoing onpump
coronary artery bypass grafting: a study on myocardial, pulmonary, renal,
intestinal, and hepatic injury. Chest 2005, 128: 2677 |
|
